Abstract
Goldman Sachs Research projects the antiobesity medication market could reach $100 billion by 2030, while J.P. Morgan forecasts the GLP-1 market will exceed $100 billion by 2030 and models ~30 million U.S. users by that time. These figures are far from mere vanity metrics; they indicate a mass consumer layer whose appetite, digestion, and food routines will be pharmacologically altered – a shift that will inevitably reorganize the supplement landscape.
The key point: GLP-1 doesn’t just reduce consumption. It changes what people can tolerate, what they fear losing while losing weight (muscle, micronutrient sufficiency, appearance), and how they shop (search behavior, basket composition, retail merchandising). The winning response is GLP-1 Companion Care, a protocol-based supplementation (protein, micronutrient density, GI tolerable formats) designed around the realities of suppressed appetite and delayed gastric emptying, and not around the fantasy of “natural Ozempic.”
Serendipity as an industry catalyst: the “Viagra Effect”
In 1998, Viagra did more than treat erectile dysfunction. It normalized a belief that biology is adjustable, and not fate. A medical product became a consumer product, and a broader “optimization” economy formed around it. GLP-1 agonists are replaying that pattern at a larger scale, with obesity care shifting into mainstream visibility and cross-industry impact.
McKinsey’s framing is blunt: GLP-1 medications are transforming obesity care, with sales expected to reach $100 billion by 2030 and prescriptions having grown 38% annually between 2022 and 2024. That scale matters because it establishes a new consumer baseline, shifting the focus from simple dieting to a sustained metabolic intervention that generates secondary needs, all of which must be addressed on a daily basis.
Interpretation: Viagra created the performance optimizer. GLP-1 is creating the metabolic optimizer, an individual who consumes less, yet requires more certainty in every remaining bite, contending with higher stakes and increased expectations.
In 1998, Viagra did more than treat erectile dysfunction. It normalized a belief that biology is adjustable, and not fate. A medical product became a consumer product, and a broader “optimization” economy formed around it. GLP-1 agonists are replaying that pattern at a larger scale, with obesity care shifting into mainstream visibility and cross-industry impact.
McKinsey’s framing is blunt: GLP-1 medications are transforming obesity care, with sales expected to reach $100 billion by 2030 and prescriptions having grown 38% annually between 2022 and 2024. That scale matters because it establishes a new consumer baseline, shifting the focus from simple dieting to a sustained metabolic intervention that generates secondary needs, all of which must be addressed on a daily basis.
Interpretation: Viagra created the performance optimizer. GLP-1 is creating the metabolic optimizer, an individual who consumes less, yet requires more certainty in every remaining bite, contending with higher stakes and increased expectations.
The post Viagra lesson is structural. Once pharma solves a “hard” biological problem, the adjacent economy grows around maintenance, confidence, and lifestyle outcomes. GLP-1 solves appetite regulation and weight loss at an unprecedented level,and immediately exposes new “soft” problems: nutrient gaps, GI tolerability, muscle loss risk, and appearance shifts.
This is why the smartest supplement strategy is not competing with GLP-1 efficacy. Instead, becoming the default companion is a way to success. The companion, he regimen consumers reach for to preserve strength, structure, and health confidence while appetite is pharmacologically suppressed.
GLP-1 is growing beyond weight loss and restructuring the consumer (and the budget)
Goldman Sachs’ $100B projection is an investment model, but it’s also a consumer budget forecast: money will be pulled from food volume and redirected into metabolic tools, nutrient density, and “health insurance” purchases. J.P. Morgan’s modeling of tens of millions of users by 2030 implies this isn’t a subculture; it’s a new layer of the mainstream.
The internal trend deck reflects the early reality: ~8–20 million Americans currently using GLP-1 drugs show strong perceived effectiveness across age groups. This discussion extends beyond the efficacy of GLP-1 to consider what follows and how brands must act as reduced appetite becomes a normalized, mass-consumer condition.
Consumer behavior trends: how GLP‑1 rewires buying, not just eating
Search behavior: demand is broadcasting itself in real time
FrontRow’s 2025 trend report shows Amazon interest spiking: searches for “GLP-1” rose +3,229% YoY in H1 2024; searches for “ozempic” rose +266%; and GLP products in Amazon’s Health category generated $2.7M in H1 2024 (+23% YoY). Rapidly outgrowing passive awareness for the power of active intent – the kind that reshapes planograms and defines the new default bundles.
Lower volume, higher value: who the GLP-1 consumer really is
Large‑scale consumer research further confirms that GLP-1 users are not a price‑sensitive or disengaged cohort. Survey data from Morning Consult [26] shows GLP-1 users over‑index on income and education and demonstrate higher purchase consideration across nearly all measured brands. This reinforces a key dynamic of the GLP-1 economy: consumption volume declines, but decision value rises. As appetite shrinks, tolerance for inefficiency disappears – favoring fewer, more trusted, and more purpose‑built solutions.
Spending behavior: GLP‑1 reduces receipts, not just calories
Cornell’s summary of research published in the Journal of Marketing Research reports that within six months of starting GLP-1 medications, households reduced grocery spending by 5.3% (more than 8% among higher-income households), and limited-service restaurant spending fell by about 8%. The reduction is category-specific: ultra-processed, calorie-dense items fell sharply, while a handful of categories (e.g., yogurt, fresh fruit) increased.
Taste and “made for me” products become higher stakes
The Consumer Trends report (survey powered by Toluna, n=518 for the GLP-1 module) states that over 90% of GLP-1 users are interested in food created specifically for them, and 52% say taste matters more since starting GLP-1 medication. This matters for supplements because it reframes compliance: if taste matters more, palatability becomes a strategic lever, not a cosmetic one.
In conclusion, appetite suppression doesn’t reduce consumer demands. It concentrates and intensifies them.
The physiology realities underlying why GLP-1 makes supplementation more consequential
A major 2025 joint advisory in The American Journal of Clinical Nutrition identifies real-world challenges that can limit GLP-1 efficacy and outcomes: GI side effects, nutritional deficiencies due to calorie reduction, and muscle and bone loss – and calls for multicomponent nutrition and lifestyle support. Here, we don’t talk about edge cases; these are predictable consequences of eating less, especially when the digestive system is altered.
Delayed gastric emptying is central. A 2025 minireview in The Journal of Clinical Endocrinology & Metabolism details clinical consequences of delayed gastric emptying with GLP-1 RAs and tirzepatide, while a 2025 review in Current Gastroenterology Reports summarizes motility effects and their implications for tolerability. The implication for brands is brutally practical: in GLP-1 physiology, low-volume, easy-to-consume delivery often beats “ideal” dosing that people can’t tolerate.
Weight-loss quality is converting the lean mass problem into a market
Lean mass loss is not hypothetical. In the SURMOUNT1 DXA sub-study, tirzepatide led to substantial weight loss, and reports that approximately 75% of the weight loss was fat mass and 25% lean mass. In the STEP1 exploratory analysis, semaglutide produced significant weight loss with reductions in fat and visceral fat and a decrease in lean mass.
The American Diabetes Association has also highlighted that lean body mass can account for up to 15–40% of total weight loss from GLP‑1 therapies, underscoring why muscle preservation is now an explicit focus area. For supplement brands, this creates a new consumer fear and a new purchase driver: “I lost weight – but did I lose strength, structure, and long-term metabolic resilience?”
The category response through GLP-1 Companion Care (not “GLP-1 boosters”)
The market is already converging on a simple truth that GLP-1 creates gaps, and gaps create a companion economy. The internal trends framing describes two routes: “natural mimics” and “companion supplements” that help mitigate the downstream effects of accelerated weight loss. The companion route is the more defensible one because it aligns with recognized issues such as micronutrient adequacy, GI comfort, and muscle preservation.
GLP‑1 Companion Care should be treated like a protocol, not a product claim:
- Protein & muscle preservation (because lean mass loss is real)
- Micronutrient density (because fewer calories increase deficiency risk)
- GI tolerable formats (because delayed gastric emptying changes compliance)
Understanding competitor strategies and the formation of the shelf
Competitor response is splitting into two plays: borrowing the hormone vs owning the outcomes.
The hormone-borrowing race (“GLP‑1 on the label”)
A BoF analysis describes the surge of GLP-1 language on supplement bottles and reports “GLP-1 supplement” searches grew 792.1% YoY in 2024 (as stated there). This is attention arbitrage: fast to launch, easy to commoditize, and increasingly credibility sensitive.
The companion-support play (side effects, gaps, retention)
Different reports highlight competitor examples positioned around muscle retention and GLP‑1 side effects, including Elo Health’s GLP‑1 muscle retention protein blend and Codeage’s companion formula. A BoF snippet also notes SoWell launched a “GLP‑1 Supplement Support” packet positioned to reduce side effects.
Retailers are already turning it into a shelf
FrontRow reports retailers highlighting formulas for GLP-1 side effects, such as electrolyte, fiber, and protein powders, and frames this as part of a broader “Ozempeconomy” where complementary products proliferate. When retailers build “GLP-1 support” modules, the winners become the brands that can simplify a protocol into repeatable purchase behavior.
Marketplace indexing: GLP‑1 support language is already in mainstream assortment
Our own Target analysis dataset includes “GLP‑1 Support” and “GLP‑1 Booster” positioning inside the vitamins/supplements assortment, indicating GLP‑1 language is already being normalized at the shelf level.
The competitive takeaway is that the winning strategy does not lie in GLP-1 branding alone; rather, it depends on building robust infrastructure that supports sustained GLP-1 adherence.
The Retail Re-Architecture Layer
Retail merchandising is shifting from ingredient‑based organization (Vitamin C, Magnesium, Collagen) to condition‑based architectures – a trend reinforced by shopper‑insights research showing GLP-1 users shop differently across categories, channels, and purchase missions.
Data from NielsenIQ and other market analyses indicate GLP-1 users are more likely to rely on auto‑ship subscriptions, shop online, and seek products labeled for energy, low‑calorie needs, or functional support. [16]
A 2025 retail trend review shows that GLP-1 medications reduce basket size while increasing intentionality, prompting retailers to recalibrate shelf messaging, layout, and assortment toward solution-based modules. [17] Behavior‑tracking analyses also show rising demand for higher protein, satiety‑oriented, and premiumized small‑format goods as appetite decreases [18].
Shopper‑experience research highlights that GLP-1 users are more easily overwhelmed by conventional shelves, abandoning purchases at higher rates when product organization lacks clarity, reinforcing the need for simplified, condition‑based navigation [19]. Industry analysts at EY Parthenon similarly describe GLP-1 as a driver of systemic change in food, beverage, and CPG retail structures [20].
Emerging retail patterns include:
- GLP-1 support bays (fiber, electrolytes, GI‑friendly protein, micronutrient density)
- Condition-based merchandising: menopause, gut repair, metabolic support
- Protocol kits and starter bundles for new GLP-1 users
- Smaller, premiumized formats to match reduced consumption volume
This mirrors earlier eras (e.g., probiotics, keto) but is more structural due to the scale and clinical nature of GLP-1 adoption.
The Food vs Supplement Convergance
GLP-1 fundamentally reshapes consumption patterns: users eat less, tolerate less variety, and seek more nutrient‑dense, GI‑gentle formats. A joint clinical advisory from major nutrition and lifestyle‑medicine bodies highlights how reduced caloric intake raises the importance of nutrient density, muscle‑supportive protein intake, and GI‑tolerable formulations, underscoring convergence between functional foods and supplementation [21].
Nutrition‑industry analyses for 2026 show accelerating innovation in protein, fiber, multifunctional beverages, and “Food as Medicine” platforms, much of it explicitly driven by GLP-1 user needs for formats that deliver more nutrition per bite [22]. Additional consensus guidance reinforces that GLP-1 therapy increases the need for personalized, nutrient‑dense diets and micronutrient adequacy, often delivered through hybrid supplement‑food solutions [23].
Global consumer‑trend research finds that GLP-1 users prefer products high in protein, fiber, and micronutrients, gravitating toward mini‑portions, functional snacks, and hybrid liquid nutrition that meet satiety and tolerability needs [24]. Precision‑nutrition analyses further show that GLP-1 physiology (delayed gastric emptying, reduced appetite, altered satiety signals) drives demand for gentle formulations, complete nutrition in small portions, and clean‑flavor products, accelerating the blurring of food and supplement categories [25].
Strategic imperative: what brands must build now
The GLP‑1 era creates a consumer who:
- searches aggressively,
- buys less volume but more deliberately,
- demands “made for me” solutions and cares more about taste,
- faces predictable nutrition and body composition risks. That combination is a call for brands to move from product marketing to regimen design.
What to build (in plain terms):
- A GLP-1 Companion protocol (protein + micronutrients + GI tolerance), grounded in what clinical guidance flags as real-world constraints.
- A format strategy that respects delayed gastric emptying and appetite suppression – the compliance physics of GLP‑1.
- An education layer that helps consumers navigate what eating less means for nutrition quality, because advice gaps are part of the problem identified in clinical guidance.
Conclusion: in plain sight
GLP‑1 is no longer a medical curiosity – it is a consumer behavior engine visible in the only places that matter: search, baskets, and shelves. When Amazon searches for “GLP‑1” rise +3,229% YoY, that is demand formation in public. When households reduce grocery spending 5.3% within six months of GLP‑1 adoption, that is wallet-share reallocation at scale. And when retailers and brands create GLP‑1 “support” merchandising, the category is being defined now – with or without you.
If you lead a wellness brand planning 2026–2027 innovation, do three things immediately:
1. Build a GLP-1 Companion Care protocol – not a single SKU.
Clinical guidance flags predictable constraints: nutrient deficiencies, GI side effects, and muscle loss risk. Design for them explicitly: protein + micronutrient density + GI tolerable delivery.
2. Design for behavior: smaller baskets, higher selectivity, higher expectations.
Over 90% of GLP-1 users’ express interest in products created specifically for them, and many report taste matters more since starting medication. Palatability is now a compliance driver – and compliance is the business model.
3. Win the shelf before the planogram freezes.
Retailers are already highlighting GLP-1 side effect support. The brands that translate GLP-1 physiology into a credible, repeatable ritual will own the repeat purchase loop – while late entrants will compete on price inside an already-defined module.
Bottom line: Don’t ask whether GLP‑1 matters. Ask whether your portfolio can serve a consumer who eats less, shops more selectively, experiments more, and needs higher nutritional certainty per serving. The GLP‑1 era is not coming – it is already shopping.
References
[1] Goldman Sachs Research: “Why the anti‑obesity drug market could grow to $100 billion by 2030.”
[2] J.P. Morgan Research: GLP‑1 market forecast and user penetration modeling.
[3] McKinsey: GLP‑1s changing obesity care; prescriptions growth and market impact.
[4] AJCN (2025): Nutritional priorities to support GLP‑1 therapy for obesity (deficiencies, muscle/bone loss, real-world challenges).
[5] JCEM (2025): Clinical consequences of delayed gastric emptying with GLP‑1 RAs and tirzepatide.
[6] Current Gastroenterology Reports (2025): GI motility effects and implications.
[7] SURMOUNT‑1 DXA substudy: body composition changes with tirzepatide.
[8] STEP‑1 DEXA exploratory analysis: semaglutide body composition outcomes.
[9] ADA press release: lean mass share of weight loss and incretin adoption growth signal.
[10] FrontRow 2025 trend report: Amazon search growth and GLP‑1 category implications.
[11] Cornell Chronicle summary of Journal of Marketing Research study: grocery and restaurant spending changes post‑GLP‑1 adoption.
[12] Internal Consumer Trends deck (n=518): “made for GLP‑1 users” interest and taste salience.
[13] BoF: wellness brands entering the Ozempic economy and GLP‑1 supplement search growth (as cited there).
[14] Internal trend file: competitor examples (Elo Health, Codeage) in GLP‑1 support positioning.
[15] Internal target assortment datasets: GLP1 support/booster language in mainstream supplements.
[16] NielsenIQ: “Marketing to GLP‑1 Users: Insights from Shopper Data.”
[17] Grow My Lifestyle: “The GLP‑1 Revolution Reshaping 2025’s Health and Retail Landscape.”
[18] Clear Research: “How GLP‑1 Medications Are Reshaping Consumer Behavior and Markets (2025).”
[19] Shopper Intelligence: “How GLP‑1 Shoppers Are Redefining Snack Choices – Insights from 2025 Data.”
[20] EY Parthenon: “The GLP‑1 Effect: Reshaping Consumption Trends in CPG and Retail.”
[21] American Journal of Clinical Nutrition: “Nutritional Priorities to Support GLP‑1 Therapy for Obesity (Joint Advisory).”
[22] Nutrition Insight: “January in Review: GLP‑1, Protein, and Fiber Drive 2026 Nutrition Trends.”
[23] The Obesity Society: “Nutritional Priorities to Support GLP‑1 Therapy for Obesity.”
[24] Innova Market Insights: “How GLP‑1 Drugs Are Reshaping Global Consumer Food Trends.”
[25] RTI International: “How GLP‑1s Are Catalyzing Precision Nutrition Innovation.”
[26] Morning Consult: “Who Is the GLP-1 Consumer? A Data-Driven Profile of America’s Most Commercially Valuable Health Segment”